Shire signs license agreement with Sandoz for generic versions of ADDERALL XR(R)

Shire plc, a UK-based biopharmaceutical company, has entered into a license agreement with Sandoz, Inc., as a part of the settlement of all pending litigations with Sandoz. Sandoz is a US-based developer, manufacturer, and distributor of generic pharmaceutical products.

This agreement provides Sandoz with a license to market Shire's own generic versions of ADDERALL XR(R) in the US beginning upon approval of its own generic products by the FDA, and Sandoz would pay Shire a royalty from those sales.

Deal Type    Partnership
Sub-Category Licensing Agreement,Marketing
Deal Status  Announced: 2009-10-13

Deal Participants

Partner 1 (Company) Sandoz, Inc. (formerly Geneva Pharmaceuticals, Inc.)
Partner 2 (Company) Sandoz International GmbH
Partner 3 (Company) Novartis AG
Partner 4 (Company) Shire plc (formerly Shire Limited)

Related terms: distributor, manufacturer, market, marketing, partnership, pharmaceuticals, products, sales